Galentin Therapeutics Inc. (OTC:GALT) has been moving down since last week. On Friday, the stock lost another 3.45% of its 
price, while its traded volume rose up.
Historical records show that GALT has not released any news on its business lately and its stock price keeps going down. Maybe, it is just the lack of fresh news that holds the current downtrend of GALT, though there is another problematic issue facing the company. It’s their financials.
Galentin filed its latest 10-Q report on Nov 10, though the results were not satisfying at all. As of September 30, GALT still had some cash and cash equivalents in its balance, however, its deficit accumulated during the development stage kept increasing. At the same time, the company’s net loss and its expenses jumped up as well.
Despite its poor financials, the management of Galentin believes that they have sufficient cash to fund the core operations through the first quarter of 2013. Nevertheless, they claim that GALT will require additional financing to fund its future operations.[BANNER]
However, just a week ago the company filed a document with the SEC pointing out all risk factors related to their business, accompanied by a warning saying that “Investing in our securities involves a high degree of risk. You should purchase these securities only if you can afford a complete loss of your investment”.
